Does Blue Cross Blue Shield of Illinois Cover Forteo?

What Is Forteo and Why Is It Prescribed?

Forteo is the brand name for teriparatide, a recombinant form of human parathyroid hormone (PTH 1-34) that stimulates new bone formation rather than simply slowing bone loss. The FDA approved Forteo in 2002 for postmenopausal women with osteoporosis at high fracture risk, and the label was later expanded to include men with primary or hypogonadal osteoporosis and patients with glucocorticoid-induced osteoporosis (FDA prescribing information).

How Teriparatide Differs From Bisphosphonates

Bisphosphonates such as alendronate work by reducing osteoclast activity, which slows bone resorption. Teriparatide, by contrast, acts as an anabolic agent. It binds the PTH-1 receptor on osteoblasts and increases bone formation directly. The Fracture Prevention Trial (N=1,637) showed teriparatide 20 mcg/day reduced new vertebral fractures by 65% and nonvertebral fragility fractures by 53% compared with placebo over a median 19 months (PubMed PMID 11794147).

Who Qualifies Clinically

The Endocrine Society's 2019 clinical practice guideline recommends anabolic agents like teriparatide for patients with very high fracture risk, defined as a FRAX 10-year major osteoporotic fracture probability of 20% or higher, a prior hip or vertebral fracture, or a bone mineral density (BMD) T-score of -2.5 or below with additional risk factors (Endocrine Society guideline, 2019). That clinical threshold directly maps to the prior authorization criteria most BCBSIL plans use.

The 24-Month Lifetime Limit

The FDA label caps cumulative teriparatide use at 24 months due to osteosarcoma findings in high-dose rat studies (FDA label, 2022). BCBSIL prior authorization approvals align with this limit. Approvals are typically issued for 6-month intervals with renewal requiring documented BMD response or continued high-risk status.

How BCBSIL Formulary Tiers Work for Specialty Drugs

BCBSIL uses a 4- or 5-tier formulary structure across its commercial, marketplace, and Medicare Advantage products. Specialty drugs like Forteo almost always land on Tier 4 (preferred specialty) or Tier 5 (non-preferred specialty), where cost-sharing is highest.

Pharmacy Benefit vs. Medical Benefit

Forteo is self-injected at home, so it typically runs through the pharmacy benefit at a specialty pharmacy. Some BCBSIL plans, particularly employer-sponsored PPOs, may route it through the medical benefit instead if a provider administers it in-office. Which benefit applies changes the deductible bucket and the cost-sharing structure, so confirming the routing with BCBSIL member services (800-654-7385 for most IL commercial members) before the first fill is worth doing.

Specialty Pharmacy Requirements

Most BCBSIL specialty drug programs require dispensing through a contracted specialty pharmacy such as Walgreens Specialty Pharmacy, Accredo, or CVS Specialty. A retail pharmacy fill may be rejected even if the drug is on formulary. The prescribing provider's office typically initiates the specialty pharmacy referral simultaneously with the prior authorization request.

Prior Authorization Criteria for Forteo on BCBSIL Plans

Prior authorization (PA) is required for Forteo on essentially all BCBSIL plan types. The specific criteria differ slightly across plan lines (commercial HMO, PPO, BlueChoice, Medicare Advantage), but the core requirements follow a consistent pattern based on published osteoporosis management guidelines.

Standard Medical Necessity Criteria

BCBSIL PA reviewers typically require all of the following to approve Forteo:

• A confirmed diagnosis of osteoporosis, defined by a DXA T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip, OR a documented low-trauma fragility fracture.
• Documentation of high or very high fracture risk, often supported by a FRAX calculation.
• A trial of at least one oral bisphosphonate (alendronate or risedronate are the most commonly required agents) at an adequate dose for a minimum of 6 to 12 months, with documented failure due to inadequate response, contraindication, or intolerance.
• Prescriber attestation that teriparatide will not exceed the 24-month cumulative lifetime limit.

The American Association of Clinical Endocrinology (AACE) 2020 Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis state: "Anabolic therapy is preferred for patients with very high fracture risk, including those with multiple vertebral fractures or very low T-scores" (AACE 2020, Endocrine Practice). BCBSIL PA criteria align with this language.

Step Therapy: The Bisphosphonate Requirement

Step therapy is the single most common reason Forteo authorizations are delayed or denied on first submission. BCBSIL plans generally require documented evidence that the patient tried an oral bisphosphonate before Forteo is approved. Exceptions apply when:

1. The patient has a documented contraindication to bisphosphonates (severe renal impairment with eGFR <30-35 mL/min/1.73m², esophageal stricture, or documented GI intolerance).
2. The patient had a bisphosphonate-related adverse event such as osteonecrosis of the jaw or atypical femoral fracture.
3. The patient has glucocorticoid-induced osteoporosis meeting ACR 2022 criteria for high fracture risk (ACR 2022 Guideline, PubMed PMID 35708018).

The HealthRX clinical team developed the following step-by-step PA submission framework based on the most common reasons BCBSIL Forteo authorizations fail on first submission:

Step 1. Obtain a complete DXA report with T-scores at all three sites and the FRAX 10-year probability. Step 2. Document the bisphosphonate trial in the chart note with dates, dose, duration, and outcome (inadequate response, adverse event, or contraindication). Step 3. Include the most recent serum creatinine/eGFR to rule out contraindication issues and to preempt the insurer's own renal clearance query. Step 4. Attach any imaging (X-ray or MRI) confirming vertebral fracture if present. Vertebral fracture documentation upgrades the clinical profile to "very high risk" and may bypass step therapy requirements. Step 5. Complete the BCBSIL-specific PA request form (available through Availity) with the ICD-10 code M81.0 (age-related osteoporosis without current pathological fracture) or M80.08 (age-related osteoporosis with current pathological fracture, vertebra) as appropriate.

How Much Does Forteo Cost With BCBSIL Insurance?

Even with coverage, Forteo is expensive. The AWP for a 28-day supply of the branded pen runs approximately $3,100 to $3,300 as of early 2025. On a Tier 4 specialty formulary, a patient's cost-sharing could range from 20% to 40% coinsurance after the deductible, which translates to $620 to $1,320 per month out of pocket before any savings programs.

Generic Teriparatide Options

Alvogen launched the first generic teriparatide (Bonsity) in the United States in late 2022, and Radius Health's Tymlos (abaloparatide), a related anabolic agent with similar mechanism, is also available. Generic teriparatide products typically carry a lower AWP and may be placed on a preferred specialty tier, reducing the patient's share. Ask the prescribing endocrinologist whether a generic teriparatide is clinically appropriate. BCBSIL may require substitution to the generic if one is on formulary (FDA generic drug database).

Eli Lilly Savings Card

For commercially insured patients who do not have government-funded insurance (Medicare, Medicaid, TRICARE), Eli Lilly's Forteo savings card program can reduce the monthly copay to as low as $4. Patients enroll at the Lilly program site or through 1-800-545-5979. The card does not apply to Medicare Part D or state Medicaid plans.

Patient Assistance Programs

Lilly Cares Foundation offers the Forteo Patient Assistance Program for uninsured or underinsured patients who meet income thresholds. Applications are submitted through the prescribing provider's office.

What to Do If BCBSIL Denies Your Forteo Prior Authorization

Denials are not final. BCBSIL, like all insurers operating in Illinois, must follow Illinois state insurance regulations and the ACA's internal and external appeals process.

Level 1 Internal Appeal

File within 180 days of the denial notice. The appeal should include:

• A letter of medical necessity from the treating physician or endocrinologist citing specific guideline language (AACE 2020, Endocrine Society 2019) and the patient's clinical data.
• The complete DXA report.
• Documentation of the bisphosphonate trial or the reason it could not be used.
• Any peer-reviewed literature supporting anabolic-first therapy for very high-risk patients.

BCBSIL must render a decision on a standard appeal within 30 days (or 72 hours for urgent/expedited appeals).

External Review

If the internal appeal is denied, Illinois residents have the right to request an independent external review through the Illinois Department of Insurance. External reviewers are not employed by BCBSIL, and their decisions are binding on the insurer. Request this review within four months of the final internal denial.

Peer-to-Peer Review

Before filing a formal appeal, the treating physician may request a peer-to-peer telephone review with a BCBSIL medical director. This call, typically 10 to 15 minutes, allows the clinician to present the case directly. Studies examining specialty drug denials across multiple payer types suggest peer-to-peer reviews resolve approximately 30 to 50% of initial denials without a formal appeal, though BCBSIL-specific data are not publicly disclosed (PubMed PMID 32730563).

Medicare Advantage and Medicare Part D Coverage of Forteo Through BCBSIL

BCBSIL offers Medicare Advantage (MA) plans in Illinois under various product lines. Forteo coverage on these plans differs from commercial coverage in important ways.

Part D Formulary Position

Under Medicare Part D, Forteo typically appears on a specialty tier with a monthly cost-sharing obligation that can exceed $200 per month even with standard coverage, since the drug price exceeds the specialty tier threshold ($700 per month as of 2024). The Inflation Reduction Act (IRA) of 2022 caps out-of-pocket drug costs for Medicare beneficiaries at $2,000 per year starting in 2025, which meaningfully changes the math for a patient using Forteo at $3,000+ per month AWP (CMS IRA drug cost provisions).

Medicare Savings Card Restriction

The Lilly Forteo savings card does NOT apply to Medicare Part D enrollees. Medicare regulations prohibit manufacturer copay assistance that could steer patients toward higher-cost branded drugs when a lower-cost alternative exists. Patients on Medicare should ask their BCBSIL MA plan about the Extra Help (Low Income Subsidy) program, which can significantly reduce Part D cost-sharing (CMS Extra Help program).

Prior Authorization on Medicare Advantage

CMS requires MA plans to use coverage criteria that are "no more restrictive" than traditional Medicare for drugs covered under Part B. For Part D specialty drugs like Forteo, MA plans retain the ability to impose prior authorization and step therapy. Illinois state law (Public Act 101-0452) requires MA plans offering products in Illinois to use a standardized PA form, which can simplify the submission process.

Alternatives to Forteo That BCBSIL May Cover at a Lower Tier

If Forteo is denied or unaffordable, several alternatives may be accessible at a lower cost-sharing tier.

Prolia (Denosumab)

Prolia (denosumab 60 mg subcutaneous injection every 6 months) is typically a Tier 3 or preferred specialty drug on BCBSIL plans. The FREEDOM trial (N=7,808) showed denosumab reduced vertebral fracture risk by 68%, hip fracture risk by 40%, and nonvertebral fracture risk by 20% over 36 months compared with placebo (PubMed PMID 19671655). Denosumab is administered in-office by a provider, which routes it through the medical benefit rather than the pharmacy benefit on most BCBSIL commercial plans.

Evenity (Romosozumab)

Romosozumab (Evenity, 210 mg monthly for 12 months) is another anabolic option. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced the risk of vertebral fracture by 48% compared with alendronate alone over 24 months (PubMed PMID 28892457). Evenity carries a black box warning for cardiovascular risk; patients with a history of myocardial infarction or stroke within the prior year are not candidates.

Oral Bisphosphonates as a Starting Point

For patients who have not yet tried a bisphosphonate, generic alendronate 70 mg weekly costs under $10 per month at most pharmacies and is on virtually every BCBSIL formulary at Tier 1. Completing this step first and documenting the outcome creates the clinical record needed for a subsequent Forteo authorization.

Verifying Your Specific BCBSIL Plan Coverage for Forteo

Coverage details vary by plan year, employer contract, and product line. Three reliable ways to confirm Forteo coverage before the first prescription is written:

1. Formulary lookup tool. Log into your BCBSIL member portal at bcbsil.com and use the drug cost estimator. Enter "teriparatide" or "Forteo" and your specific plan. The tool shows tier placement, PA requirement, and estimated cost-sharing.
2. Benefits verification call. Call the BCBSIL member services number on the back of your insurance card. Ask specifically: (a) Is Forteo on formulary? (b) What tier? (c) Is prior authorization required? (d) Is step therapy required? (e) Is there a specialty pharmacy requirement?
3. Provider-initiated PA check. The prescribing endocrinologist or rheumatologist's office can run an electronic PA eligibility check through Availity or CoverMyMeds before submitting, which returns an instant indication of whether PA will be required and the specific criteria BCBSIL applies to the member's plan.

Clinical Context: How Fracture Risk Guides Coverage Decisions

Insurance prior authorization criteria do not exist in isolation. They reflect published clinical guidelines, which themselves are built on fracture risk evidence.

FRAX Thresholds and PA Approval Probability

The FRAX tool calculates 10-year probability of hip fracture and major osteoporotic fracture using BMD, age, sex, and clinical risk factors (FRAX tool via NOF, ncbi.nlm.nih.gov review PMID 17161432). Most BCBSIL PA criteria for anabolic agents like Forteo align with the National Osteoporosis Foundation threshold of 20% or higher for major osteoporotic fracture or 3% or higher for hip fracture as the minimum for pharmacologic treatment. Patients with scores above these thresholds and a documented bisphosphonate trial have the strongest PA approval profiles.

DXA Documentation Requirements

A DXA scan performed within the preceding 24 months is typically required for PA submission. The report must include T-scores at the lumbar spine (L1-L4), femoral neck, and total hip. If the DXA was performed at an outside facility, the full radiology report must be attached to the PA request; a verbal T-score from a clinic note is rarely sufficient for BCBSIL reviewers.

Glucocorticoid-Induced Osteoporosis as a Fast Track

Patients taking the equivalent of prednisone 7.5 mg/day or more for 3 months or longer qualify for the high-risk glucocorticoid-induced osteoporosis category under ACR 2022 guidelines (PubMed PMID 35708018). BCBSIL may waive bisphosphonate step therapy for this patient group, since the ACR guideline conditionally recommends anabolic therapy as initial treatment for very-high-risk patients on long-term glucocorticoids.